Overview

Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)

Status:
Recruiting

Trial end date:
2025-12-29

Target enrollment:

Participant gender:

Summary

The main objective of this clinical study is to evaluate the safety of XS005 cell which contains Natural Killer (NK) cells and culture-expanded injection; to determine the maximum tolerated dose . Furthermore, initial efficacy will be examined.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Dushu Lake Hospital Affiliated to Soochow University

Treatments:

Temozolomide